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Abstract (100 words) 
Background 
In the absence of definitive data about the natural history of DCIS the appropriateness of 
describing DCIS as cancer is controversial.   
Methods 
We conducted a survey amongst British Breast Group (BBG) members, to determine which 
descriptions of DCIS were deemed most accurate and appropriate.  
Results 
54/73 (74%) attendees completed the survey: A majority (34/54; 63%) said they would be 
comfortable using the description that explained DCIS as abnormal cells in the milk ducts 
that had not spread into other breast tissue and which did not need urgent treatment as if it 
was breast cancer and this description was overall the most preferred (24/54; 44%). 
Conclusions 
Little consensus exists regarding how best to explain low grade DCIS to patients.  
Keywords 
Low grade DCIS; breast screening; clinicians’ views   
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Introduction 
Ductal Carcinoma in situ (DCIS) is a difficult condition to define and consequently 
explanation of it divides opinion amongst cancer specialists.1 It is variously described as 
precancerous, pre-invasive, non-invasive or intraductal breast cancer.  There is debate as to 
whether DCIS should ever be described as cancer and this can generate confusion amongst 
patients diagnosed with DCIS.2  Interview studies report that women were shocked and 
concerned when told they needed a mastectomy for a condition that is non-invasive3. Most 
women had not heard of DCIS before their diagnosis despite it being included in an NHS 
patient information screening leaflet4.  
Since the introduction of the NHS Breast Screening Program (NHSBSP) in 1988, the 
incidence of DCIS has increased markedly and represents approximately 20% of screen 
detected cancers.5 A recent review of the NHSBSP by Professor Sir Michael Marmot 
considered the benefits and harms of mammographic screening and recognised that some 
women with screen-detected lesions are overtreated.6    
DCIS is divided into 3 grades; low, intermediate and high.  Data regarding the natural 
progression of DCIS is sparse, so it is nearly always treated as if it is invasive cancer 
regardless of grade. This over-diagnosis-overtreatment conundrum is worrying many 
worldwide and prompted the United States National Cancer Institute (USNCI) to suggest 
removing ‘carcinoma’ from DCIS and describe it as ‘ductal intraepithelial neoplasia’ instead, 
or even IDLE – InDolent Lesion of Epithelial origin.7 More recently the National Institute of 
Health (NIH) convened an expert group in 2012 to provide other suggestions.  There was a 
consensus that antiquated nomenclature such as DCIS needed updating and thresholds for 
what should be regarded as abnormal raised.8 
A DCIS diagnosis can be perplexing as well as distressing for patients; often they are told 
that they may have a very early form of breast cancer that needs immediate treatment in the 
absence of any apparent tumour.  Treatment may include mastectomy, confusing women 
even further especially if they know of other patients with manifest invasive breast cancer 
who only require a wide local excision. It can appear illogical to have no lump but ‘very early 
breast cancer’ that necessitates mastectomy3.  There are trials being conducted worldwide 
that aim to measure the outcome of different management policies for low and 
low/intermediate grade DCIS. It is vital to ensure that all recruiting clinical teams are 
comfortable when describing low grade DCIS and that women receive consistent 
information. A randomised trial of surgery versus active monitoring for LOw RISk DCIS 
(LORIS)9. has recently been launched in the UK. We wished to determine which descriptions 
of DCIS would prove most acceptable for use in trial literature and when discussing the trial 
with women. 
Methods 
Design  
We designed a questionnaire based survey eliciting the views of breast cancer experts about 
how best to describe low and low intermediate grade DCIS to patients.   
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The Questionnaire 
First we conducted an Internet search eliciting the many different but commonly used 
descriptions of DCIS: these were reviewed by three researchers.  Four descriptions from 
high profile cancer charity websites (Macmillan, Cancer Research UK (CRUK), Breast 
Cancer Care and Breast Cancer Campaign) were chosen as they are all well-known and 
trusted amongst the general public. The descriptors were mainly found under the heading of: 
“What is DCIS?” and usually provided a summary of DCIS with further information on the 
website under other sub-titles.  The way in which DCIS was described differed substantially, 
for example one said DCIS was the earliest possible form of breast cancer whereas another 
said that it can be described as pre-invasive, intra-ductal or non-invasive cancer. Members 
of the LORIS trial team created a fifth description, which we considered provided a more 
balanced and accurate description of DCIS. Table 1 shows the final five DCIS descriptors 
used.   
To avoid any biases the survey descriptors were not labelled with their source and were 
presented in a counter-balanced order to avoid all respondents being exposed to the same 
descriptor first, thus five versions of the questionnaire were produced. Respondents were 
initially asked if they would be comfortable (yes or no) using each descriptor when talking to 
patients about low and low intermediate grade DCIS. They then indicated their most 
preferred and most disliked descriptions.  If respondents disliked all options provided they 
were invited to write their own DCIS description. 
Results 
Respondents 
The paper-based survey questionnaire was completed by 54/73 (74%) healthcare 
professionals attending the British Breast Group meeting in February 2013, 35 males (35/54; 
64.8%), and 14 females (14/54; 25.9%).  The different professional disciplines included 
surgeons (22/54; 40.7%), oncologists (13/54; 24%), radiologists (7/54; 13%), scientists 
(7/54; 13%), pathologists (3/54; 5.6%), an endocrinologist (1/54; 1.8%) and a cancer 
geneticist (1/54; 1.8%). 
Table 1 shows the proportions of respondents who would feel comfortable using different 
descriptors with patients. Most appeared comfortable with that devised by the LORIS team 
34/54 (63%), followed closely by the CRUK description (29/54; 54%).  
Respondents (36/54; 66.6%) were least comfortable with the Macmillan description.  This 
was mirrored across all professional groups, with 70% (14/20) surgeons, 85% (6/7) 
radiologists, 66.7% (2/3) pathologists and 75% (9/12) of oncologists.  
If respondents were not comfortable using any of the five descriptors they provided their 
own. Analysis of this free text showed the division of opinion about DCIS as cancer e.g. one 
surgeon wrote: 
“I say it is pre-cancer and it can become cancer if left behind” 
Whereas another stated: 
"You need to emphasize it is not cancer" 
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Seven of the 10 wrote their own descriptions, broadly mentioned DCIS as not life threatening 
and three stated that DCIS was cancer. Four stated that if DCIS was left untreated it could 
turn into an invasive breast cancer.  Four respondents said they used diagrams and similes 
when discussing DCIS with patients.   
Table 1 also shows the most and least preferred descriptions; 3 respondents had no 
preference and 3 chose two.  
Most preferred was that devised by the LORIS Team; (44%; 24/54). This was independent of 
professional group or sex.  It was preferred by 67% (14/21) surgeons, 86% (6/7) radiologists, 
33% (1/3) pathologists and 58% (7/12) oncologists.   
Discussion 
Definitions of DCIS available on the websites that patients might access are inconsistent. 
The results of this survey amongst breast cancer specialists, demonstrate that it is a difficult 
condition to describe. There is particular disagreement amongst experts about the use of the 
word cancer.  
It is common for patients to consult the internet for more information about their diagnosis.  
Prominent and well publicised cancer charities are trusted and often accessed first.  This 
survey showed that descriptions used by breast specialists and those found on charity 
websites vary creating difficulties for patients and doctors treating them if terminology used 
is inconsistent.   
The Cancer Research UK (CRUK) description of DCIS was the longest used in the survey; 
(a couple of respondents commented that it was too lengthy), but it does have a very clear 
diagram showing the difference between DCIS and invasive breast cancer.  Using diagrams 
to explain difficult concepts are often helpful and a few of the respondents surveyed said that 
they like to use diagrams when explaining DCIS to a patient.   
The least preferred descriptor from Macmillan was the briefest, however none of the 
respondents of the survey made comments about its brevity.  Importantly since our survey 
was completed Macmillan has updated their website extensively, with very comprehensive 
information about DCIS and diagrams of normal cells and cells forming a tumour.  The 
Breast Cancer Care website has a useful 12 page booklet providing information about 
diagnosis, treatment and different grades of DCIS that can be downloaded or hard copies 
ordered. The main body of their text used to describe DCIS has remained unchanged to that 
used in this survey.   
Breast Cancer Campaign’s website description is the same as that used in the survey and 
includes information about research they fund including the genetics, biology and spread of 
DCIS as well as the emotional impact of a diagnosis of DCIS for women.   
The LORIS description of DCIS was preferred regardless of gender and across all clinical 
specialties; importantly 63% of respondents would feel comfortable using it even if it was not 
their preferred description.  The LORIS team comprised a surgeon, oncologist, trials co-
ordinator and two psycho-oncologists who elicited views from a variety of sources including 
patients as to the most user-friendly, accurate and informative means of describing DCIS 
without mentioning phrases such as early form of cancer. 
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Most survey respondents were clinicians who have to discuss the diagnosis of DCIS and its 
management with patients. Different results might have been obtained if the survey had 
been conducted with more pathologists.  
The LORIS trial opened June 2014 and is accompanied by a patient friendly information 
DVD that uses the most preferred description found in our survey. Healthcare professionals 
should also check that the websites that they suggest patients might access for further 
information is congruent with what has been said in clinic. 
Although the results of our survey were limited by the small sample size we hope that they 
might contribute to the ongoing debate as to how DCIS is best described. Patients with low 
grade DCIS cannot make informed choices about trial entry or treatment without consistent 
information. 
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Appendix A: Web addresses of cancer charities 
http://www.macmillan.org.uk 
http://www.cancerresearchuk.org/cancer-help/type/breast-cancer/about/types/dcis-ductal-
carcinoma-in-situ  
www.breastcancercampaign.orghttp://www.breastcancercampaign.org/about-breast-
cancer/breast-screening/ductal-carcinoma-in-situ 
http://www.breastcancercare.org.uk/breast-cancer-information/about-breast-cancer/primary-
breast-cancer/types%C2%A0of%C2%A0primary%C2%A0breast%C2%A0cancer/ductal-
carcinoma-situ-dcis 
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Table 1 Summary of main results 
Description Comfortable 
Yes 
N(%) 
Comfortable  
No 
N(%) 
Most Preferred 
description 
N(%) 
Least Preferred 
description  
N(%) 
LORIS TMG: DCIS stands for ‘Ductal Carcinoma in Situ’ and 
means that there are abnormal cells in the milk ducts of the 
breast. This has not spread into any other breast tissue. Before 
breast screening took place a diagnosis of DCIS was rare but 
now it is common. DCIS looks like specks of white (calcium) on 
a mammogram.  
When doctors look at DCIS under the microscope they can split 
it into different grades – high, intermediate and low.  
High grade DCIS cells look more like invasive breast cancer 
cells. Because high grade is more likely to turn into breast 
cancer, it is treated as though it is. Many doctors are uncertain if 
low or intermediate DCIS would ever become invasive breast 
cancer. Some feel that it needs watching, but doesn’t need 
urgent treatment as if it was breast cancer. 
34/54 
(63) 
18/54 
(33) 
24  
(42) 
6  
(11) 
Cancer Research UK: If you have ductal carcinoma in situ 
(DCIS), it means that cells inside some of the ducts of your 
breast have started to turn into cancer cells. These cells are all 
contained inside the ducts and have not started to spread into 
the surrounding breast tissue. So, there is very little chance that 
any of the cells have spread to the lymph nodes or elsewhere in 
the body. Doctors use various terms to describe DCIS, including 
pre invasive, non-invasive, or intraductal cancer. 
Your doctor may describe DCIS as a very early form of breast 
cancer. If it is not treated, in some women DCIS starts to spread 
into the surrounding breast tissue after some years. So it may 
become an invasive cancer. DCIS is being found more often 
than in the past. It is sometimes picked up by mammograms 
when women are screened for breast cancer. Nearly 4,650 
29/54 
(54) 
 
          22/54 
         (41) 
16 
(28) 
7 
(13) 
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women are diagnosed with DCIS in Great Britain each year. 
DCIS and invasive ductal breast cancer are not the same thing. 
In invasive ductal breast cancer, the cells have broken out of the 
ducts and spread into the surrounding breast tissue. There is 
then a chance that the cells can spread into nearby lymph nodes 
or other parts of the body 
Breast Cancer Campaign: DCIS is a non-invasive type of 
breast cancer which is confined to the breast’s milk ducts and 
has not spread into the surrounding breast tissue. We don’t 
know enough about the condition to reliably predict which cases 
of DCIS will progress to invasive breast cancer, and therefore 
debate has arisen about its routine detection and treatment.  The 
detection of some cancers which may not cause harm to women 
in their lifetime, for example Ductal Carcinoma In Situ, or DCIS is 
often discussed in relation to over-diagnosis of breast cancer. 
19/54 
(35) 
32/54 
(59) 
7  
(12) 
9  
(17) 
Breast Cancer Care: DCIS is an early form of breast cancer, 
where the cancer cells have developed within the milk ducts but 
remain there ‘in situ’ having not yet developed the ability to 
spread outside the ducts into the surrounding breast tissue or to 
other parts of the body. You may hear DCIS described as a pre-
invasive, intraductal or non-invasive cancer. Occasionally you 
may also hear it incorrectly described as pre- cancerous.  
Both men and women can develop DCIS, however it is very rare 
in men. As a result of being confined to the breast ducts, a 
diagnosis of DCIS has a very good prognosis (outlook). 
23/54 
(42) 
29/54 
(54) 
4  
(7) 
8  
(15) 
Macmillan: Ductal Carcinoma In Situ (DCIS) is the earliest 
possible form of breast cancer and is non-invasive. Although 
DCIS needs to be treated, it isn’t a life-threatening condition. 
Surgery is the most common treatment. 
 
15/54 
(27) 
36/54 
(66) 
3  
(5) 
17  
(32) 
Total   57* (100) 54 (100) 
*Total of 57 as 3 people had more than one preference 
 
